Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.77 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.77 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.77 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.77 |
| ▸ | DHFR | P00374 | 1/20 | 0.77 |
| ▸ | MPO | P05164 | 1/20 | 0.77 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834970 | 1.00 | AKR1C3 (0.77) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| SCHEMBL355549 | 0.88 | FABP4 (0.80) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| SCHEMBL30320327 | 0.88 | FABP4 (0.80) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| Mefenamic Acid SCHEMBL6421234 | 0.87 | PTGS2 (1.00) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| Mefenamic Acid SCHEMBL29465887 | 0.87 | PTGS2 (1.00) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| Mefenamic Acid SCHEMBL29355128 | 0.87 | PTGS2 (1.00) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| Mefenamic Acid SCHEMBL29350572 | 0.87 | PTGS2 (1.00) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| Mefenamic Acid SCHEMBL3544 | 0.87 | PTGS2 (1.00) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| SCHEMBL6140897 | 0.87 | AKR1C3 (0.70) | AKR1C3MEN1PTGS2KMT2AAKR1B10 | |
| SCHEMBL4186922 | 0.87 | AKR1C3 (0.60) | AKR1C3MEN1PTGS2KMT2AAKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339236-A1 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-10-27 | — | — | US | claimed |
| EP-4034097-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE MRNAS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2022-08-03 | — | — | EP | claimed |
| WO-2021059270-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-04-01 | — | — | WO | claimed |
| CN-109516946-A | A method of preparing carbazole compound | 上海交通大学 | 2019-03-26 | — | — | CN | claimed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| CN-111057004-B | N-o-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof | 宁波大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-112745237-B | 2-arylamine compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| US-20220339236-A1 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-10-27 | — | — | US | disclosed |
| EP-4034097-A2 | TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE MRNAS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2022-08-03 | — | — | EP | disclosed |
| CN-113683615-A | Evodiamine derivative and preparation and application thereof | 南华大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-112745237-A | 2-arylamine compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2021-05-04 | — | — | CN | disclosed |
| WO-2001056992-A2 | DIBENZO (B,F) AZEPINE INTERMEDIATES | NOVARTIS AG (CH) | 2001-08-09 | — | — | WO | disclosed |
| EP-0252603-A2 | Adhesives for ceramics and processes for the bonding of ceramics using same | MITSUI SEKIYU KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1988-01-13 | — | — | EP | disclosed |
| EP-0073155-B1 | COMPOUNDS HAVING ANTITUMOUR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4537729-A | ANTITUMOR AGENTS | DEVELOPMENT OF FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1985-08-27 | — | — | US | disclosed |
| US-4479000-A | ANTITUMOR AGENTS | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1984-10-23 | — | — | US | disclosed |
| EP-0073155-A2 | Compounds having antitumour activity | WARNER-LAMBERT COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4273873-A | BONDING SYNTHETIC FIBRINOLYTIC COMPOUND OR ENZYME | UNITIKA LTD. (JP) | 1981-06-16 | — | — | US | disclosed |
| US-4024127-A | Process for the preparation of 5-alkyl-10-amino-dihydrodibenzoazepines | RHONE-POULENC S.A. (FR) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | MAPT, TTR, HTT | AKR1C3 3315/4885MEN1 2502/4885PTGS2 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.